These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1794623)

  • 1. Correlations between virus infection and pathogenicity in humans.
    Agut H; Huraux JM
    Dev Biol Stand; 1991; 75():211-7. PubMed ID: 1794623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus evolution within patients increases pathogenicity.
    Iwasa Y; Michor F; Nowak MA
    J Theor Biol; 2005 Jan; 232(1):17-26. PubMed ID: 15498589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Operator-induced contamination in cell culture systems.
    Hay RJ
    Dev Biol Stand; 1991; 75():193-204. PubMed ID: 1794620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human retroviruses and herpesviruses: problems and solutions in safety testing of biologicals.
    Onions D; Lees G
    Dev Biol Stand; 1991; 75():145-58. PubMed ID: 1794616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal vaccination and the evolution of viral pathogens.
    Schat KA; Baranowski E
    Rev Sci Tech; 2007 Aug; 26(2):327-38. PubMed ID: 17892155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viruses and assuring viral safety.
    Robertson JS
    Dev Biol (Basel); 2003; 113():73-7. PubMed ID: 14620855
    [No Abstract]   [Full Text] [Related]  

  • 13. The little-known determinants of virus pathogenicity.
    Smith H
    Scand J Infect Dis Suppl; 1980; Suppl 24():119-27. PubMed ID: 6163198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Emergent viral infections].
    Galama JM
    Ned Tijdschr Geneeskd; 2001 Mar; 145(13):616-9. PubMed ID: 11305210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 17. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 19. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses.
    Pocchiari M
    Dev Biol Stand; 1991; 75():87-95. PubMed ID: 1794633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.